Pfizer Inc. (NYSE:PFE) will release its third quarter earnings report before the opening bell on Tuesday, Nov. 3.
Analysts expect the New York-based company to report quarterly earnings of 73 cents per share, down from 87 cents per share in the year-ago period. The consensus estimate for PFE’s quarterly revenue is $15.88 billion. It reported $16.65 billion last year, according to Benzinga Pro.
On Oct. 27, Pfizer released topline results from its Phase 3 MagnetisMM-32 study evaluating Elrexfio (elranatamab) as a monotherapy.
Shares of Pfizer gained 0.5% to close at $30.67 on Monday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
- JP Morgan analyst Chris Scott maintained a Neutral rating and raised the price target from $28 to $30 on Oct. 9, 2026. This analyst has an accuracy rate of 68%.
- Cantor Fitzgerald analyst Carter Gould maintained a Neutral rating and increased the price target from $27 to $28 on Oct. 8, 2026. This analyst has an accuracy rate of 68%.
- Scotiabank analyst Louise Chen maintained the stock with a Sector Outperform rating and boosted the price target from $30 to $33 on Oct. 6, 2026. This analyst has an accuracy rate of 61%.
- HSBC analyst Rajesh Kumar maintained a Hold rating and boosted the price target from $28 to $30 on Sept. 10, 2026. This analyst has an accuracy rate of 56%.
- Guggenheim analyst Vamil Divan maintained a Buy rating and cut the price target from $35 to $31 on Aug. 7, 2026. This analyst has an accuracy rate of 78%.
Considering buying PFE stock? Here’s what analysts think:
Photo via Shutterstock